The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Reporting to the Director, Business Operations - G&A, the ideal candidate is equally comfortable moving between planning, project execution, process improvement, data analysis, and stakeholder problem-solving, serving as both an operational project lead and analytical thought partner within an exciting, dynamic and fast-moving environment.